Synopsis
FDA is taking action to accelerate Neuroscience Medical Product Development NAIN brings together scientific and regulatory expertise from FDA's Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH).
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
